eISSN 2508-3589
pISSN 2508-1926

Table. 3.

Table. 3.

The changes of central macular thickness in the bevacizumab group and dexamethasone group

Baseline 1 month 2 months 3 months 4 months 5 months 6 months
BVZ 424.20 ± 103.25 356.07 ± 64.82 339.25 ± 76.06 347.67 ± 80.74 353.78 ± 81.51 396.67 ± 156.75 370.38 ± 102.19
p-value* - 0.023 0.015 0.02 0.028 0.753 0.046
DEX 435.60 ± 71.71 271.00 ± 33.04 300.75 ± 60.89 354.60 ± 90.38 419.67 ± 173.41 281.33 ± 50.21 301.20 ± 45.76
p-value* - 0.005 0.035 0.042 0.113 0.016 0.038
p-value 0.405 <0.001 0.078 0.912 0.11 0.02 0.046

Mean change in CMT from baseline during the follow-up period. Values are presented as mean ± standard deviation. CMT = central macular edema; BVZ = bevacizumab group; DEX = dexamethasone implant group.

Wilcoxon signed rank test vs. baseline;

Mann whitney U test.

J Retin 2019;4:84-92 https://doi.org/10.21561/jor.2019.4.2.84
© 2019 J Retin